Christine Fox
Executive Vice President, U.S. Commercial
Christine (Chris) Fox was appointed Executive Vice President, U.S. Commercial on November 20, 2023, leading all commercial activities for Teva in the U.S., including our generics, biosimilars and innovative medicines business.
Chris brings more than 30 years of healthcare industry experience with leadership roles in sales, marketing, and commercial operations, responsible for teams ranging from 2500+ associates to small, nimble consulting teams. She has a deep understanding of issues affecting the pharmaceutical and biotech sectors, as well as expertise across a range of therapy areas.
Prior to Teva, Chris served as President at Novartis Gene Therapies since December 2021. Previously, Chris was vice president and general manager for the Bone, Cardiometabolic and Nephrology business for Amgen. She also served as the general manager of the company’s United Kingdom and Ireland affiliate. Earlier in her career, she also held leadership positions at Merck, Takeda, and several startups.
Richard Francis
President and Chief Executive Officer, Member of the Board of Directors
Richard Daniell
Executive Vice President, European Commercial
Dr. Eric A. Hughes
Executive Vice President, Global R&D and Chief Medical Officer
Placid Jover
Executive Vice President, Chief Human Resources Officer
Eli Kalif
Executive Vice President, Chief Financial Officer (CFO)
David McAvoy
Executive Vice President, Chief Legal Officer
Mark Sabag
Executive Vice President, International Markets Commercial
Matthew Shields
Executive Vice President, Teva Global Operations
Nir Baron
Senior Vice President, Chief Internal Auditor
Kathleen Veit
Senior Vice President, Global Compliance & Ethics Officer
At Teva, we strive to deliver quality medicines to patients around the world with integrity and ethical business practices. What we do is important, but how we do it is just as important. Learn more:
Cookie SettingsCopyright © 2024 Teva Pharmaceutical Industries Ltd.